Literature DB >> 10619682

In vitro investigation of the blood response to medical grade PVC and the effect of heparin on the blood response.

N M Lamba1, J M Courtney, J D Gaylor, G D Lowe.   

Abstract

This paper reports the results of an investigation into the blood response of polymers in vitro, using non-anticoagulated and heparinised blood and plasma. The materials studied were regenerated cellulose, (Cuprophan), an acrylonitrile-allyl sulphonate copolymer (AN69S), and medical grade polyvinyl chloride plasticised with di-2-ethyl-hexyl-phthalate (PVC/DEHP). Blood-material or plasma-material contact was achieved using a parallel plate flow cell, and C3a generation and FXII-like activity measured. The results of the study with non-anticoagulated human blood show that PVC/DEHP is a high complement activator. C3a concentration in the blood was higher after contact with PVC/DEHP than after contact with regenerated cellulose. The introduction of heparin in the blood induced complex alterations in the blood response. C3a generation could be elevated, decreased, or remain the same, depending on the material. The FXII-like activity on the surface of the PVC/DEHP after contact with plasma was also higher than the other two polymers. The introduction of heparin could increase or decrease FXII-like activity, depending on material. The patterns of response obtained with non-anticoagulated blood in vitro for AN69S and Cuprophan bore a strong resemblance with patterns of response obtained in the clinic, whereas those obtained with heparinised blood in vitro did not.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10619682     DOI: 10.1016/s0142-9612(99)00145-3

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

1.  Fabrication of thromboresistant multilayer thin film on plasma treated poly (vinyl chloride) surface.

Authors:  Qinggang Tan; Jian Ji; Feng Zhao; De-Zeng Fan; Fu-Yu Sun; Jia-Cong Shen
Journal:  J Mater Sci Mater Med       Date:  2005-07       Impact factor: 3.896

2.  In vitro biocompatibility evaluations of hyperbranched polyglycerol hybrid nanostructure as a candidate for nanomedicine applications.

Authors:  Ali Zarrabi; Mohammad Ali Shokrgozar; Manouchehr Vossoughi; Mehdi Farokhi
Journal:  J Mater Sci Mater Med       Date:  2013-11-30       Impact factor: 3.896

Review 3.  Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review.

Authors:  Sarah C Skinner; Vimal K Derebail; Caroline J Poulton; Donna C Bunch; Prabir Roy-Chaudhury; Nigel S Key
Journal:  Kidney Med       Date:  2021-06-09

4.  In vitro investigation of the effect of plasticizers on the blood compatibility of medical grade plasticized poly (vinyl chloride).

Authors:  Rui Zhong; Hong Wang; Xia Wu; Ye Cao; Zeng He; Yuliang He; Jiaxin Liu
Journal:  J Mater Sci Mater Med       Date:  2013-05-18       Impact factor: 3.896

5.  Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride.

Authors:  Rolf Dario Frank; Ute Mueller; Regina Lanzmich; Jürgen Floege
Journal:  J Mater Sci Mater Med       Date:  2013-07-18       Impact factor: 3.896

6.  Blood interactions with plasticised poly (vinyl chloride): influence of surface modification.

Authors:  Xiaobin Zhao; James M Courtney; Hua Q Yin; Robin H West; G D O Lowe
Journal:  J Mater Sci Mater Med       Date:  2007-07-10       Impact factor: 3.896

7.  Complement Deposition and IgG Binding on Stored Red Blood Cells Are Independent of Storage Time.

Authors:  Astrid J F Thielen; Elisabeth M Meulenbroek; Inge Baas; Robin Bruggen; Sacha S Zeerleder; Diana Wouters
Journal:  Transfus Med Hemother       Date:  2018-03-09       Impact factor: 3.747

8.  Main Chain Polysulfoxides as Active 'Stealth' Polymers with Additional Antioxidant and Anti-Inflammatory Behaviour.

Authors:  Farah El Mohtadi; Richard d'Arcy; Xiaoye Yang; Zulfiye Yesim Turhan; Aws Alshamsan; Nicola Tirelli
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.